People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Pharmaceuticals, Medical Devices, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Amplyx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $116.6M | $3.2B | 2017 |
| Synedgen, Inc. | — | Pharmaceuticals | Series A | $24.3M | $8.2M | 2016 |
| Nanomedical Diagnostics, Inc. | — | Medical Devices | Series A | $12.0M | $37.9M | 2020 |
| Numira Biosciences Inc | — | Biotechnology | Seed | $3.3M | $145.8M | 2009 |
| Crisprqc Inc. | — | Biotechnology | Pre-Seed | $1.8M | $5.6M | 2024 |
Paul Grint at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Grint on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Heltzen | 2 | 2 |
| Ross Bundy | 2 | 2 |
| Dinesh Patel | 1 | 13 |
| Edward Mathers | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Michael Grey | 1 | 10 |
| John Morgan | 1 | 9 |
| Andrew Miller | 1 | 8 |
| ANAND MEHRA | 1 | 7 |
| Alan Fuhrman | 1 | 5 |
| Nina Saberi | 1 | 5 |
| Mitchell Mutz | 1 | 5 |
| Biao He | 1 | 5 |
| Johan Kordel | 1 | 4 |
| Joseph Keegan | 1 | 4 |
| Karen Talmadge | 1 | 3 |
| David Weinstein | 1 | 3 |
| Elaine Heron | 1 | 3 |
| WILLIAM WIESMANN | 1 | 2 |
| Shenda Baker | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.